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Abstract 
Background: The best predictors of short- and medium-term mortality of cirrhotic patients receiving intensive care 
support are unknown.
Methods: We conducted meta-analyses from 13 studies (2523 cirrhotics) after selection of original articles and 
response to a standardized questionnaire by the corresponding authors. End-points were in-ICU, in-hospital, and 
6-month mortality in ICU survivors. A total of 301 pooled analyses, including 95 analyses restricted to 6-month mortal-
ity among ICU survivors, were conducted considering 249 variables (including reason for admission, organ replace-
ment therapy, and composite prognostic scores).
Results: In-ICU, in-hospital, and 6-month mortality was 42.7, 54.1, and 75.1%, respectively. Forty-eight patients 
(3.8%) underwent liver transplantation during follow-up. In-ICU mortality was lower in patients admitted for variceal 
bleeding (OR 0.46; 95% CI 0.36–0.59; p < 0.001) and higher in patients with SOFA > 19 at baseline (OR 8.54; 95% CI 
2.09–34.91; p < 0.001; PPV = 0.93). High SOFA no longer predicted mortality at 6 months in ICU survivors. Twelve 
variables related to infection were predictors of in-ICU mortality, including SIRS (OR 2.44; 95% CI 1.64–3.65; p < 0.001; 
PPV = 0.57), pneumonia (OR 2.18; 95% CI 1.47–3.22; p < 0.001; PPV = 0.69), sepsis-associated refractory oliguria 
(OR 10.61; 95% CI 4.07–27.63; p < 0.001; PPV = 0.76), and fungal infection (OR 4.38; 95% CI 1.11–17.24; p < 0.001; 
PPV = 0.85). Among therapeutics, only dopamine (OR 5.57; 95% CI 3.02–10.27; p < 0.001; PPV = 0.68), dobutamine 
(OR 8.92; 95% CI 3.32–23.96; p < 0.001; PPV = 0.86), epinephrine (OR 5.03; 95% CI 2.68–9.42; p < 0.001; PPV = 0.77), 
and MARS (OR 2.07; 95% CI 1.22–3.53; p = 0.007; PPV = 0.58) were associated with in-ICU mortality without hetero-
geneity. In ICU survivors, eight markers of liver and renal failure predicted 6-month mortality, including Child–Pugh 
stage C (OR 2.43; 95% CI 1.44–4.10; p < 0.001; PPV = 0.57), baseline MELD > 26 (OR 3.97; 95% CI 1.92–8.22; p < 0.0001; 
PPV = 0.75), and hepatorenal syndrome (OR 4.67; 95% CI 1.24–17.64; p = 0.022; PPV = 0.88).
Conclusions: Prognosis of cirrhotic patients admitted to ICU is poor since only a minority undergo liver transplant. 
The prognostic performance of general ICU scores decreases over time, unlike the Child–Pugh and MELD scores, even 
recorded in the context of organ failure. Infection-related parameters had a short-term impact, whereas liver and renal 
failure had a sustained impact on mortality.
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Background
The natural course of liver cirrhosis is often punctuated by 
life-threatening complications requiring admission to an 
intensive care unit (ICU) [1]. Critically ill cirrhotic patients 
were reported to have poor prognosis [2–4], but recent 
data suggest improvements due to significant progress in 
the management of general in-ICU populations, and a bet-
ter understanding of the pathophysiology of cirrhosis [5–
7]. The generalization of standardized interventions, such 
as management of portal hypertension-related bleeding, 
has contributed to a survival gain in this population. How-
ever, survival after hospital discharge remains low in cir-
rhotic patients [3, 8–10]. Numerous studies have focused 
on prognostic factors of cirrhotic patients admitted in ICU 
but provided short-term and controversial results, possibly 
impacted by selection biases. In the more recent studies on 
the topic, the performances of some isolated characteris-
tics such as acute kidney injury [11–14], need for mechan-
ical ventilation [3, 15, 16], septic shock [5, 17], and of 
liver-specific or general ICU scores [2, 7, 18–21] to predict 
mortality have been compared but the design was often 
retrospective and reflected a single-center experience. As a 
consequence, no evidence-based recommendation regard-
ing the admission of critically ill cirrhotic patients to ICUs 
can be made [22]. More importantly, the long-term prog-
nosis of the patients who survived to intensive care and its 
determinants has been poorly documented.
The aim of this meta-analysis was therefore to compare 
the prognostic value of a large set of variables on in-ICU, 
in-hospital, and 6-month mortality in patients who sur-
vived the ICU phase.
Methods
Literature search (Additional file 1: Figure S1)
Computer searches for eligible studies were performed 
in April 2014 using PubMed, Cochrane Library, and 
EMBASE, with the following combination of key words: 
«cirrhosis» OR «cirrhotic» AND «intensive care» OR 
«ICU» OR «critically ill» in the title AND «prognosis» 
OR «survival» OR «outcome» OR «mortality» in the title 
or abstract, with a publication date ranging from January 
2004 to March 2014. Reference lists of identified articles 
were also manually searched for additional relevant pub-
lications. Two main authors (DW and VDM) selected 
independently studies published as full papers in English, 
and in the event of divergence on studies’ selection, a con-
sensus was reached through discussion. The study design 
could be prospective or retrospective, but the main out-
come measure of the study had to be survival.
Data collection
Because the published studies were not fully compara-
ble, a standardized questionnaire was sent to the principal 
investigators of eligible studies asking them to extract from 
their database the distribution of survivors and non-survi-
vors at each time point (in ICU, in hospital, at 6 months after 
discharge from ICU) for 249 variables. To avoid any hetero-
geneity in the answers, qualitative variables were defined if 
necessary, and units of each quantitative variable were given 
in the questionnaire. Quantitative variables were presented 
as intervals or cutoffs, according to their clinical relevance. 
The queries were focused on (1) characteristics of the center 
(primary/tertiary, having or not a liver transplantation pro-
gram, a dedicated Hepatology department, TIPS being or 
not routinely performed) and of the ICU (general or special-
ized for liver diseases, involved or not in the postoperative 
follow-up after liver transplantation, strategies for limitation 
of life-sustaining treatments being available or not), num-
ber of ICU admissions per year, and proportion of cirrhotic 
patients; (2) period of inclusion; (3) baseline patient char-
acteristics (age, sex, history of cirrhosis, main reason for 
admission in ICU, clinical and biological characteristics); 
(4) biological and clinical characteristics during ICU stay; 
(5) therapeutics used during ICU stay (required or not on 
admission); (6) prognostic scores including Child–Pugh and 
MELD scores, SOFA and its variation between baseline and 
day 3, modified SOFA (mSOFA), CLIF-SOFA, APACHE-II, 
and number of non-hematologic organ failures.
Statistical analyses
For each variable, pooled analyses comparing survivors 
and non-survivors were performed. We used the Der-
Simonian and Laird model for random effects to obtain 
summary estimates across studies. Results were expressed 
by the combined weight-adjusted odds ratios (OR), with 
their 95% confidence interval (95% CI). A p value (from 
directional zero-effect test) of 0.05 or less was considered 
statistically significant. We tested for heterogeneity using 
Cochran’s Q test (considered significant at p ≤ 0.05). Posi-
tive and negative predictive values were calculated for sig-
nificant results. This report follows the MOOSE guidelines 
for reporting meta-analyses of observational studies [23].
Results
Study characteristics
We selected 30 studies published between January 01, 
2004, and March 31, 2014, including 6030 patients. Nine 
authors (ten studies) could not be contacted [15, 24–27] 
or did not answer [16, 20, 28–30]; three authors (five stud-
ies) agreed to participate but did not return the question-
naire [13, 17, 31–33]; two authors had no longer access to 
the database [9, 34]. Finally, we received 11 answers, cov-
ering 13 studies (2523 patients, Table 1; Additional file 1: 
Figure S1) [2, 3, 5–8, 10, 35–40]. Studies from Jenq et al. 
[37, 38] and from Levesque et al. [2, 3] were grouped for 
avoiding double-counting patients in the meta-analyses.
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Center characteristics
The 13 studies came from ten tertiary centers, of which 
eight had a liver transplantation program and nine had 
a hepatology department. In seven centers, TIPS was 
routinely performed. Of the ten ICUs, seven were gen-
eralized ICUs and nine had strategies for limitation of 
life-sustaining therapies available. The total number of 
ICU admissions per year was >1000 in four centers and 
<500 in one center. The reported proportion of cirrhotic 
patients was <5% in three centers, 5–10% in one, 10–20% 
in one, and >20% in three centers.
Data recorded
In-ICU mortality was reported in ten studies (1904 
patients), in-hospital mortality in 12 studies (2446 patients), 
and 6-month mortality in five studies (828 patients).
Of the 249 listed variables, 92 were available in none 
or only one questionnaire and thus could not be further 
analyzed. The majority of them were related to events 
occurring during ICU stay.
Study population and major outcome events
The patients’ characteristics on ICU admission are 
detailed in Additional file  1: Table S1. Briefly, two-third 
of patients were males and <60 years; cirrhosis was alco-
hol-related in 58.4% and associated with hepatocellular 
carcinoma in 11.7% of cases; the main primary reason for 
admission was variceal bleeding.
Overall, 814 patients (42.7%) died in the ICU, 1322 
(54.1%) died in hospital, and 622 (75.1%) had died at 
6  months. Among the studies, in-ICU, in-hospital, and 
6-month mortality ranged from 34.3 to 71.9, 39.4 to 83.1, 
and 56.6 to 86.5%, respectively (Fig. 1). Among the 1240 
patients with available information, only 48 (3.8%) under-
went liver transplantation within the first 6  months of 
follow-up. The majority (45 patients) were transplanted 
within the first 3 months. The reasons why patients did 
or did not undergo liver transplantation were not given.
Predictors of short‑term mortality
For each meta-analysis, Additional file  1: Tables S2 and 
S3 show the weight-adjusted combined OR, its 95% CI, 
and the positive and negative predictive values for mor-
tality. A selection of the more relevant predictors of in-
ICU mortality is given in Fig. 2.
Center characteristics
Centers with a liver transplantation program were asso-
ciated with higher in-ICU mortality. Centers without 
routine TIPS programs had higher in-hospital mortal-
ity. Conversely, in-ICU and in-hospital mortality was not 
different in centers having a dedicated liver department 
or not, in ICUs involved in post-transplantation care or 
not, in centers with or without available strategies for 
limitation of life-sustaining therapies, in high-volume or 
low-volume centers regarding the total number of ICU 
Fig. 1 Overall survival. In-ICU, in-hospital, 3-month, and 6-month survival rates are reported for each study included (thin and dotted lines) and for 
the whole study population (heavy black line). On the x-axis, the timescale is not complied, given the variable length of stay in ICU and hospital
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admissions or the proportion of cirrhotic patients admit-
ted to ICU per year.
Period of inclusion
The inclusion period ranged from 1995 to 2012. In-ICU 
mortality was higher in studies with inclusions before the 
year 2004 [5, 6, 10] versus others. The same results were 
observed for in-hospital mortality.
Demographics and history of cirrhosis
Age <40 years was associated with lower in-ICU (Figs. 2 
and 3) and in-hospital mortality. Age >60 years was asso-
ciated with higher in-hospital mortality, but results were 
not significant for in-ICU mortality. Sex had no influ-
ence on short-term mortality. The outcome of patients 
with alcohol-induced cirrhosis did not differ from that of 
patients with other causes (Figs. 2 and 3). 
Circumstances of admission
Mortality was not different in patients directly admitted 
to ICUs as compared to patients who were previously 
hospitalized. Among the reasons for admission, variceal 
bleeding was associated with lower in-ICU mortality 
(Fig.  3), whereas septic shock was associated with poor 
outcome, but with heterogeneous results (Additional 
file 1: Table S2 and Fig. 2).
SIRS and sepsis
SIRS was associated with higher in-ICU (Fig. 2) and in-
hospital mortality. Baseline CRP levels >29  mg/L were 
associated with higher in-ICU mortality. Sepsis-induced 
hypotension was associated with higher in-ICU and in-
hospital mortality. In septic patients, refractory oliguria 
was a strong predictor of in-ICU and in-hospital mortal-
ity. Nosocomial and community-acquired infections had 
similar outcomes (Fig.  2). Patients with positive blood 
culture, pneumonia, or infection of unusual site were at 
higher risk of death in-ICU. Spontaneous bacterial peri-
tonitis only impacted on in-hospital mortality. Gram-
negative bacillus infections were associated with higher 
in-ICU mortality. Fungal infection was associated with 
higher in-ICU (Figs. 2 and 3) and in-hospital mortality.
Respiratory function and hemodynamics
A PaO2  <  60  mmHg at baseline was associated 
with higher in-ICU and in-hospital mortality. A 
PaCO2  >  50  mmHg was associated with higher in-ICU 
mortality. A pH <7.3 was associated with higher in-hos-
pital mortality, but results were heterogeneous for in-
ICU mortality. A PaO2/FiO2 ratio <100 was associated 
with higher in-ICU mortality. A baseline mean arterial 
pressure <65 mmHg was associated with poor short-term 
outcome, but pooled analyses provided heterogeneous 
results. High lactate levels at baseline were associated 
with higher in-ICU and in-hospital mortality.
Renal function
Four markers of renal function at baseline were reported 
for all studies. Hepatorenal syndrome did not impact on 
in-ICU or in-hospital mortality. A serum creatinine level 
>2 mg/dL was associated with higher in-hospital and in-
ICU mortality, but results were heterogeneous. Results 
were also heterogeneous for serum creatinine >1.5  mg/
dL and oliguria, defined as urine output ≤20 mL/h.
Neurological status
Among the five available markers of neurological sta-
tus, none had significant impact on mortality without 
heterogeneity.
Medical interventions and organ replacement therapies
Investigators were queried about 15 medical interven-
tions, including nine drugs and three organ replacement 
therapies. Of these, only ten interventions could be stud-
ied. Answers were insufficient for nutritional support and 
the use of insulin, hydrocortisone, and N-acetylcysteine. 
The most relevant information for prognosis was given by 
the use of epinephrine, which was associated with higher 
in-ICU and in-hospital mortality. The use of dopamine 
and dobutamine was associated with higher in-ICU mor-
tality. The use of norepinephrine, regardless of its indica-
tion (hemodynamic support or hepatorenal syndrome), 
provided heterogeneous results in terms of in-ICU mor-
tality. The use of somatostatin was associated with lower 
in-ICU mortality. Among organ replacement therapies, 
(See figure on previous page.) 
Fig. 2 Predictors of in-ICU mortality. For each variable, combined weight-adjusted odds ratios (filled triangle) and their 95% confidence intervals 
(horizontal line) obtained from forest plots of pooled analyses are reported, together with the p value, the number of cirrhotic patients with variable 
present, and the total number of patients with available data. Odds ratios >1 correspond to variables associated with higher mortality. Odds ratios 
<1 correspond to variables associated with better survival. Odds ratios with a 95% CI containing 1 correspond to nonsignificant results. (*) indicates 
heterogeneous results. APACHE Acute Physiology and Chronic Health Evaluation, CRP C-reactive protein, GNB Gram-negative Bacilli, GPB Gram-
positive Bacilli, MARS molecular adsorbents recirculation system, MELD model of end-stage liver disease, NHOF non-hematologic organ failure, NS 
not significant, SIRS systemic inflammatory response syndrome, TIPS transjugular intrahepatic portosystemic shunt, SOFA Sequential Organ Failure 
Assessment, mSOFA modified SOFA, CLIF-SOFA modified SOFA according to the Chronic Liver Failure Consortium of the European Association for the 
Study of the Liver
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Fig. 3 Some remarkable results regarding in-ICU mortality (forest plots of odds ratios)
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MARS was associated with in-ICU and in-hospital mor-
tality. Mechanical ventilation and renal replacement 
therapy were also associated with poorer short-term out-
comes, but the results were heterogeneous (Fig. 2).
Prognostic scores
Twenty-four analyses regarding the relevance of prog-
nostic scores for predicting mortality at each given 
time were performed. The number of organ failures 
strongly impacted on in-ICU mortality. A SOFA  >  19, 
a CLIF-SOFA  ≥  22 (Fig.  3), and an APACHE-II  ≥  30 
were strongly associated with higher in-ICU mortality, 
whereas values of the mSOFA provided heterogeneous 
results (Figs. 2 and 3). Increased SOFA at day three was 
given in only two studies, covering 267 patients. It was 
associated with higher in-ICU and in-hospital mortality. 
A Child–Pugh stage A was associated with lower in-ICU 
mortality. Results were heterogeneous for the Child–
Pugh stage C. High MELD scores were associated with 
in-ICU mortality. In-hospital mortality was best pre-
dicted by a baseline MELD ≥ 13.
Predictors of 6‑month mortality in ICU survivors
Variables with an impact on outcome of the 412 patients 
who survived the ICU phase are shown in Figs. 4 and 5 
and Additional file 1: Table S4. General ICUs, high-vol-
ume centers, or centers with a routine TIPS program had 
lower mortality, whereas centers with a liver transplan-
tation program had higher mortality. Age, sex, etiology 
of cirrhosis and duration of ICU stay had no significant 
influence. Parameters of liver function recorded on 
ICU admission such as bilirubin >3  mg/dL, INR  >  2.3, 
MELD > 26, and Child–Pugh C stage had a strong influ-
ence. Renal impairment was also deleterious as assessed 
by hepatorenal syndrome prior to admission, renal failure 
as a reason for ICU admission, or need for renal replace-
ment therapy. Other remarkable predictors were septic 
shock, nosocomial infection, and high leukocytes count 
at baseline. Among the ICU prognostic scores, high lev-
els of SOFA did not impact on 6-month mortality, nor 
did an increase in SOFA at day three, conversely to high 
levels of CLIF-SOFA or APACHE-II.
Discussion
Our meta-analysis investigated numerous characteristics 
of a large population of cirrhotic patients from different 
centers. It enabled us to provide original data regard-
ing 6-month mortality in more than 400 patients who 
survived intensive care. It yields four major findings: (1) 
despite in-ICU mortality rates below 50% and decreas-
ing in the more recent studies, medium-term progno-
sis remained poor and this finding was reproducible 
between studies. One possible explanation could be that 
a very small proportion of patients underwent liver trans-
plantation; (2) short-term mortality was well predicted by 
ICU scores, which reflect the degree of organ dysfunc-
tion; (3) bad ICU score results at baseline did not predict 
6-month mortality in ICU survivors. In those patients, 
the major determinants of outcome were liver and renal 
failure, underlining the value of the MELD; the CLIF-
SOFA, that incorporates parameters of liver function, 
was the only score able to predict both in-ICU and mid-
term survival; (4) some events considered alone, mostly 
related to SIRS and sepsis, were strong predictors of poor 
short-term prognosis, with performance similar to that of 
composite scores.
This analysis confirms that in-ICU survival was sig-
nificantly better in patients admitted after 2004. This 
improvement in short-term prognosis over time sug-
gests that substantial progress has been achieved in the 
management and/or selection of critically ill cirrhotic 
candidates for ICU. However, the dramatic decrease in 
medium-term survival illustrates the fragility of these 
patients and the limits of available efficient therapies 
beyond the initial control of organ failures allowing ICU 
discharge. Liver transplantation was rarely performed, 
even in centers with liver transplantation program avail-
able, and to date, this option appears to be inadequate 
to solve the problem. This finding is in keeping to what 
shown by a recent US study, in which only a small pro-
portion of liver recipients (8.1%) comes from ICUs [41]. 
This is surprising, since liver transplantation of criti-
cally ill patients has been reported to provide acceptable 
results in some critically ill patients [42, 43]. Hence, the 
“sickest-first” policy applied in the USA and Europe to 
(See figure on next page.) 
Fig. 4 Predictors of 6-month mortality in ICU survivors. For each variable, combined weight-adjusted odds ratios (filled triangle) and their 95% 
confidence intervals (horizontal line) obtained from forest plots of pooled analyses are reported, together with the p value, the number of cir-
rhotic patients with variable present, and the total number of patients with available data. Odds ratios >1 correspond to variables associated with 
higher mortality. Odds ratios <1 correspond to variables associated with better survival. Odds ratios with a 95% CI containing 1 correspond to 
nonsignificant results. (*) indicates heterogeneous results. APACHE Acute Physiology and Chronic Health Evaluation, CRP C-reactive protein, GNB 
Gram-negative Bacilli, GPB Gram-positive Bacilli, MARS molecular adsorbents recirculation system, MELD model of end-stage liver disease, NHOF 
non-hematologic organ failure, NS not significant, SIRS systemic inflammatory response syndrome, TIPS transjugular intrahepatic portosystemic 
shunt, SOFA Sequential Organ Failure Assessment, mSOFA modified SOFA, CLIF-SOFA modified SOFA according to the Chronic Liver Failure Consor-
tium of the European Association for the Study of the Liver
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Fig. 5 Some remarkable results regarding the impact of characteristics recorded on ICU admission on the 6-month mortality in ICU survivors (forest 
plots of odds ratios)
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allocate liver grafts should give high priority to this popu-
lation, providing the rigorous selection of patients in the 
context of organ shortage, by discarding those with dis-
seminated hepatocellular carcinoma, severe comorbidi-
ties, uncontrolled sepsis, and presumed non-compliance, 
especially regarding alcohol consumption. All these 
points justify referring ICU survivors to a liver transplant 
center for careful evaluation.
In most studies, age was not reported to have an 
independent influence on mortality in this population, 
appearing only as a component of the APACHE score. In 
our study, one spectacular finding was the better progno-
sis of patients <40 years, who represent a small propor-
tion of each cohort but can be adequately studied through 
meta-analysis. This finding is contrary to a recent study 
in which younger patients were supposed to have more 
severe acute on chronic liver failure (ACLF) [44]. Patients 
admitted to ICU for variceal bleeding had better short-
term outcomes. This probably results from the more gen-
eral use of pharmacological and endoscopic therapies, 
and TIPS, which efficiently control variceal bleeding. 
Pooled analyses of other reasons for admission suggested 
poor outcome, but were heterogeneous. Hence, indica-
tions other than variceal bleeding cannot be considered 
as deleterious per se. Similarly, results were heterogene-
ous regarding the impact of organ replacement therapy 
on ICU mortality. In particular, mechanical ventilation 
per se did not equal death, contrary to what Rabe et al. 
suggest [15]. The MARS system, perhaps because it was 
allocated to the sickest patients, was a strong surrogate 
for in-ICU mortality. This indicates that MARS is not 
powerful enough to cure multi-organ failure in cirrhotic 
patients, and should rather be considered as a bridge to 
liver transplantation.
Our study confirms the power of composite scores to 
predict in-ICU mortality. Among them, the SOFA was 
largely used and the recent CLIF-SOFA [45], although 
not used by the majority of authors at the time of their 
studies, provided strong predictions. The APACHE-II 
score was not widely used in cirrhotic patients, probably 
because of its complexity, and/or because of liver failure, 
which renders the interpretation confusing. These gen-
eral scores were better than the liver-specific scores for 
the prediction of in-ICU mortality. It is acknowledged 
that short-term prognosis mostly depends on the number 
of organ failures and that scoring liver failure provides 
limited prognostic information in patients with multi-
organ failure. Conversely, MELD and Child–Pugh, even 
measured in the context of organ failures, were able to 
predict 6-month mortality among ICU survivors. Inter-
estingly, the APACHE-II and CLIF-SOFA, more influ-
enced by liver failure than the SOFA, maintained their 
predictive value after ICU discharge. Moreover, we found 
that among the extrahepatic organ failures, renal failure 
was more powerful for the prediction of 6-month mor-
tality in patients who survived ICU than for the predic-
tion of in-ICU mortality. This is in keeping with results 
already reported by Fede et  al. [14] and reinforces the 
value of the MELD score. The question of repeated 
evaluation of patients at day three, supported by some 
landmark papers [8, 46, 47], was also evaluated by our 
meta-analysis. Only a small proportion of patients (10%) 
had available SOFA at day three, thus decreasing the 
power of our pooled analyses. As a consequence, changes 
in SOFA between baseline and day 3 did not provide bet-
ter predictions than baseline evaluations. This raises the 
question of the acceptability of this procedure, which 
supposes the interruption of organ support in the event 
of aggravation.
Another major result of our study is the impact of SIRS 
and sepsis in the outcome of cirrhotic patients admitted 
to ICU. The pejorative influence of SIRS and infection 
has been shown in non-ICU populations of cirrhot-
ics [25, 48]. Our meta-analysis demonstrates that this is 
still true in the most severe cirrhotic patients regardless 
of the reason for admission in ICU. In particular, fungal 
infection, an event often associated with a delay in initi-
ating the appropriate antimicrobial therapy, had a strong 
negative influence. Gram-negative infections were also 
significantly associated with mortality, highlighting the 
deleterious impact of endotoxinemia in the natural his-
tory of cirrhosis [25]. Pneumonia and its consequences 
were clearly a challenge for intensive care specialists, 
whereas spontaneous bacterial peritonitis, a surrogate of 
end-stage liver disease, had a deleterious influence in the 
longer term.
Our study acknowledges several limitations. First, the 
need of original data led to lack of exhaustiveness since 
a substantial proportion of authors was unable to share 
their data and answer our questionnaire. Second, because 
of missing data and/or recall biases, our meta-analyses 
of events that occurred during ICU stay were probably 
inaccurate. Third, among the 301 pooled analyses per-
formed in the present work, 108 provided heterogeneous 
results and the source of heterogeneity was unknown. 
This is why we decided not to take heterogeneous results 
into account in our conclusions. Fourth, we did not study 
prognostic scores recently described, such as the quick 
SOFA [49] and the Besançon’s score [21], because they 
were not available at the time of study conception. The 
prognostic impact of ACLF was also incompletely stud-
ied because this condition was not defined at the time 
of some studies. Only a retrospective assessment of 
ACLF as a reason for admission could be studied, with 
no significant impact on mortality. Fifth, the design of 
this meta-analysis only allowed separate assessments of 
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weight-adjusted pooled odds ratios for a single variable 
at different follow-up timepoints, but did not allow us to 
combine variables for analyses. However, correct mul-
tivariate analyses must include truly independent vari-
ables, and we assume that, in the context of multi-organ 
failures, clinical condition, biochemical parameters, and 
interventions are intricate. Sixth, because individual data 
were not available in the present study, it was not possi-
ble to provide new information regarding which patients 
could be considered futile for intensive care, and to con-
firm or not the conclusions from the CANONIC cohort 
recently published [44].
Conclusions
Our analysis indicates that admission to ICU should be 
envisaged as soon as possible for critically ill cirrhotic 
patients, before too many extrahepatic failures compro-
mise short-term survival. ICU survivors without heavy 
comorbidities can be identified early and may be system-
atically considered for transplantation. The number and 
intensity of organ failures on ICU admission does not 
mask the power of MELD score measured concomitantly 
for predicting 6-month mortality and thus immediately 
discriminates the best candidates for liver transplantation. 
The CLIF-SOFA is relevant for discriminating both in-ICU 
and mid-term mortality in critically ill cirrhotic patients.
Study highlights
What is already known on this subject?
  •  The outcome of cirrhotic patients admitted to ICUs 
is poor but varies between centers.
  •  Numerous prognostic scores have been tested in this 
situation, only focused on short-term mortality.
What are the new findings?
  • We report the predictors of mid-term survival in 
patients who survive the ICU phase.
  •  We observe a good predictive value of MELD score 
measured at baseline (ICU admission), even in the 
context of multi-organ failures, to predict mid-term 
mortality.
How might it impact on clinical practice in the foreseeable 
future?
  • Early discrimination of patients who will survive the 
ICU phase but with remaining risk of mortality after 
discharge will accelerate the access to liver transplan-
tation of the good candidates, today not systemati-
cally considered.
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